搜索结果

   MLN

靶点ID:TCMBANKGE008139

靶点别名:-

靶点描述:motilin

染色体:6

染色体位置:6p21.31

靶点类型:protein-coding

HERB_ID:-

HGNC_Link:7141

OMIM_Link:158270

Ensembl_Link:ENSG00000096395

   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族
   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN008636 acetylcholine Vagusstoff; AC1NSTAT; Acetylcholine Hydroxide; 2-acetyloxyethyl(trimethyl)azanium hydroxide; SCHEMBL3904052; 56-13-3 C7H16NO2+ 146.21 g/mol CC(=O)OCC[N+](C)(C)C
TCMBANKIN016334 (-)-noradrenaline to_000024; 1,2-Benzenediol, 4-[(1R)-2-amino-1-hydroxyethyl]-; KBio3_001579; CHEBI:18357; NCGC00159406-02; 4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol; Levoarterenol; KBio2_006625; KBio1_000230; L-Noradrenaline; NCGC00159406-05; Nor adrenalin (TN); Nor adrenalin; Noradrenaline (JP15); NINDS_000230; 4-[(1R)-2-amino-1-hydroxy-ethyl]pyrocatechol; Spectrum_001009; norepinephrinum; SPECTRUM1500436; KBio2_004057; Spectrum3_000520; KBio2_001489; DivK1c_000230; nchembio705-1; PDSP1_001111; 4-[(1R)-2-amino-1-hydroxy-ethyl]benzene-1,2-diol; 51-41-2; 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-; KBioSS_001489; C00547; NCGC00159406-04; BSPBio_002079; AIDS335520; A7257_SIGMA; KBioGR_000635; D00076; (−)-Norepinephrine; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-(-)-; Spectrum5_001068; Arterenol; Spectrum4_000078; PDSP2_001095; Spectrum2_001064; (-)-(R)-Norepinephrine; SGCUT00123; AIDS-335520; Norepinephrine (INN); SPBio_001048; IDI1_000230 C8H11NO3 169.18 C1=CC(=C(C=C1C(CN)O)O)O
TCMBANKIN057939 ribitol AKOS015915193; SCHEMBL15318; meso-xylitol; (2R,3r,4S)-pentane-1,2,3,4,5-pentol; MolPort-044-875-282; D-Xylitol; s4546; UNII-YFV05Y57M9 component HEBKCHPVOIAQTA-SCDXWVJYSA-N; 84709-28-4; BRN 1720524; Wood sugar alcohol; Xylitol, Pharmaceutical Secondary Standard; Certified Reference Material; HY-100582; Ribitol (Adonitol); AKOS015903403; Adonitol, BioXtra, >=99.0% (HPLC); 127873-EP2377841A1; Adonito; 87849-01-2; Xylitol [USAN]; 353ZQ9TVDA; bmse000129; Xylitol, Vetec(TM) reagent grade, >=99%; Xylitol, European Pharmacopoeia (EP) Reference Standard; Pentitot; N1725; HEBKCHPVOIAQTA-ZXFHETKHSA-N; Xylitol, United States Pharmacopeia (USP) Reference Standard; NSC 25283; Klinit; 1,2,3,4,5-Pentahydroxypentane; 1,2,3,4,5-PentahydroxypentaneXylite; bmse000886; Kylit; 75398-81-1; Xylitab 100; Xylitab DC; MolPort-003-934-322; DB01904; HEBKCHPVOIAQTA-NGQZWQHPSA-N; 2088-EP2377849A2; ZINC100018612; CS-2987; 7313-55-5; 4-01-00-02832 (Beilstein Handbook Reference); Tox21_201056; Adonitol, BioReagent, suitable for cell culture; Adonitrot; UNII-YFV05Y57M9 component HEBKCHPVOIAQTA-ZXFHETKHSA-N; Xylisorb 700; Adonitot; (2R,3S,4S)-Pentane-1,2,3,4,5-pentaol; LS-162656; DSSTox_RID_80046; DS-11416; BG01499408; 2088-EP2311842A2; 2088-EP2314584A1; I14-19011; DTXSID7042514; Epitope ID:114703; CHEBI:15963; SCHEMBL4250; xylitol; L-xylitol; Epitope ID:114702; 6684F574-C267-40CB-8828-12F2550E58D0; CHEBI:17151; 127873-EP2275398A1; 2088-EP2292612A2; FT-0631414; NCGC00165982-01; EINECS 201-788-0; WURCS=1.0/1,0/[h111h]; Fluorette; EC 201-788-0; 1,2,3,4,5-Pentanot; 2088-EP2292234A1; HY-N0538; A0171; HEBKCHPVOIAQTA-SCDXWVJYSA-N; (2S,4R)-pentane-1,2,3,4,5-pentol; I14-7373; ST50411707; Xylitol, >=99%; D-ribitol; QSPL 191; Xylitab 300; MolPort-003-895-940; K573; 127873-EP2374783A1; (2R,3R,4S)-Pentane-1,2,3,4,5-pentaol; (2S,4R)pentane-1,2,3,4,5-pentaol; C00379; 127873-EP2295402A2; Xylitol, analytical standard; K-9195; 87-99-0; (2R,3s,4S)-Pentane-1,2,3,4,5-pentot; Xylite; MFCD00064291; (2R,3s,4S)-pentane-1,2,3,4,5-pentol; 2088-EP2371811A2; (2R,4S)-pentane-1,2,3,4,5-pentol; SCHEMBL1924966; Xyliton; UNII-VCQ006KQ1E; Ribitol (6CI,8CI,9CI); CHEMBL3137744; 12426-00-5; WURCS=1.0/1,0/[h121h]; 2088-EP2272822A1; BRN 1720523; 5DCF4F57-E023-469A-B4F3-91E8349A6705; Xylite (sugar); 488-81-3; L-ribitol; HSDB 7967; MLS002695898; Eutrit; AC1L1NKP; RB0; bmse000062; Adonit; s2612; 2088-EP2301938A1; I14-19012; C00474; Adonitol (7CI); Xylisorb 300; CS-6043; adonitol; 84709-42-2; 1,2,3,4,5-pentanepentol; Xylitol [INN:BAN:JAN:NF]; KS-00000Y00; Ribitol, Adonite, 488-81-3; AC1Q59QK; NCGC00258609-01; DSSTox_GSID_42514; UNII-353ZQ9TVDA; CHEMBL96783; AK307743; Xylit; ZINC100014205; C5H12O5; 2088-EP2305254A1; X-7000; ZINC18068098; 37191-59-6; AK307317; Adonitol, >=99%; Adonite; MFCD00064292; CHEMBL1865120; NSC 16868; EINECS 207-685-7; meso-ribitol; 2088-EP2284162A2; DSSTox_CID_22514; 1,2,3,4,5-Pentanepentot; VCQ006KQ1E; 16277-71-7; 2088-EP2284163A2; D-Adonitol; E967; Xylitol C; Newtol; Kannit; ribitol; CCG-214167; FT-0656634; xylo-Pentitol; 2088-EP2275417A2; Xylisorb; NCGC00165982-02; CAS-87-99-0; SMR001562099; Adonitt; 28296-13-1;Xylitol;Adonitol C5H12O5 152.15 g/mol C(C(C(C(CO)O)O)O)O
TCMBANKIN057965 arginine L(+ )-arginine;EINECS 230-571-3; (2S)-2-amino-5-guanidino-pentanoic acid; EINECS 200-811-1; (S)-2-Amino-5-guanidinovaleric acid; DL-Arginine; (L)-Arginine; Arginine hydrochloride(USAN); 1-Amino-4-guanidovaleric acid; L-Ornithine, N5-(aminoiminomethyl)-; W381918_ALDRICH; (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid; Arginine [USAN:INN]; S-(+)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid; L-Arginine, labeled with tritium; AI3-24165; AIDS-121865; (S)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid; NSC203450 (HYDROCHLORIDE); A5006_SIAL; (+-)-Arginine; L-Norvaline, 5-((aminoiminomethyl)amino)-; AIDS121865; Lopac0_000077; Tocris-0663; Arginine (VAN); 4455-52-1; CCRIS 3609; BRN 1725413; NCGC00015064-01; (2S)-2-amino-5-(carbamimidamido)pentanoic acid; (2S)-2-amino-5-guanidinopentanoic acid; D02982; Argininum [INN-Latin]; C00062; 7200-25-1; A8094_SIGMA; 11009_FLUKA; Poly(L-arginine); (2S)-2-amino-5-guanidino-valeric acid; Lopac-A-5006; NSC 206269; HSDB 1429; CHEBI:16467; L-Arginine, homopolymer; L-Arginine (9CI); Arginina [INN-Spanish]; 4-04-00-02648 (Beilstein Handbook Reference); (S)-2-amino-5-guanidinopentanoic acid; (S)-2-Amino-5-((aminoiminomethyl)amino)pentanoic acid; Arginine, L- (8CI); L-Arginine (JP15); EU-0100077; L-alpha-Amino-delta-guanidinovaleric acid; NSC7914 (HYDROCHLORIDE); Arginine (USP); 1119-34-2 (HYDROCHLORIDE); Pentanoic acid, 2-amino-5-((aminoiminomethyl)amino)-, (S)-; L-Arg; L-Norvaline, 5-[(aminoiminomethyl)amino]-; 142-49-4; A4474_SIAL; InChI=1/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s; L-Arginin; Arginine, DL-; NCGC00024715-01;AC1ODX8E; [(4S)-5-amino-4-azaniumyl-5-oxopentyl]-(diaminomethylidene)azanium; [AMINO({[(4S)-4-AMMONIO-4-CARBAMOYLBUTYL]AMINO})METHYLIDENE]AZANIUM C6H14N4O2 174.2 g/mol C(CC(C(=O)O)N)CN=C(N)N
TCMBANKIN057975 lysine acid C6H14N2O2 146.19 g/mol C(CCN)CC(C(=O)O)N
TCMBANKIN058425 serotonine AC1L1JTO; Oprea1_712368; KBio2_007608; Tryptamine, 5-hydroxy-; NCGC00142449-02; Ds substance; 6996AB; NCGC00015525-08; Bio2_000396; 14C-5-hydroxy tryptamine creatinine disulfate; KBioGR_002472; 6F7FD5B4-A558-45F0-A20A-2D068A3EFE6A; NCGC00015525-06; NCGC00142449-03; CHEMBL39; Prestwick1_000481; NCGC00015525-02; KBio3_000843; CH-132; ALBB-006183; FT-0631212; MolPort-001-779-633; BRN 0143524; 3-(.beta.-Aminoethyl)-5-hydroxyindole; PDSP1_001512; 1H-Indol-5-ol, 3-(2-aminoethyl)-; KBio2_005040; AX8011985; KBioGR_000452; 5-Hydroxytryptamine, free base; DTXSID8075330; NCGC00142449-04; KBio3_002950; Indol-5-ol, 3-(2-aminoethyl)-; Substanz DS; Antemovis; KBio2_000452; L000078; IDI1_002151; Prestwick0_000481; 5-Hydroxy-3-(beta-aminoethyl)indole; AC1Q54C0; serotonin; Prestwick2_000481; LS-83647; 5-Hydroxytryptamine, 5-HT, Enteramine; KBio2_002472; Hippophain; 5-hydroxy-tryptamine; KBio2_005588; Substance DS; SPBio_002262; 2-imino-1-methylimidazolidin-4-one; 3-(2-aminoethyl)-1H-indol-5-ol; bis(sulfuric acid); Biomol-NT_000083; BDBM10755; HMS3403H13; AKOS001484724; NCGC00015525-05; C-06146; HMS1362H13; 5-Hydroxytriptamine; API0006544; I14-1899; ZINC57058; HMS1990H13; Bio2_000876; KB-177045; A-Aminoethyl)-5-hydroxyindole, Thrombotonin; Thrombocytin; CC-21879; NCGC00015525-09; NCGC00142449-05; 3-(2-Aminoethyl)-1H-indol-5-ol #; Enteramine; KBioSS_002479; HMS1792H13; 5-Hydroxy-3-(.beta.-aminoethyl)indole; CAS-153-98-0; 5-Hta; STK503758; GTPL5; KBio3_000844; CTK4J2994; 5-22-12-00016 (Beilstein Handbook Reference); Thrombotonin; 5-hydroxyl tryptamine; AJ-09556; Serotonine; Thrombocytin, 3-(; Bio1_001428; BCBcMAP01_000198; cMAP_000059; EINECS 200-058-9; 5-Hydroxyltryptamine; K-9367; Hippophaine; 3-(beta-Aminoethyl)-5-hydroxyindole; DB-051820; 50-67-9; C00780; BPBio1_001079; Prestwick3_000481; BSPBio_001112; 5-Hydroxy-3-(b-aminoethyl)indole; 333DO1RDJY; SMP1_000272; MCULE-8788459983; Lopac0_000607; H-8000; AK115646; D0F6CD; NCGC00015525-07; 3-(b-Aminoethyl)-5-hydroxyindole; Lopac-H-9523; Bio1_000450; Antemoqua; 5-HYDROXYTRYPTAMINE; BPBio1_000377; TR-018115; Serotonin, analytical standard; KBio2_003020; 3-(2-Aminoethyl)indol-5-ol; STOCK1N-48365; KBioSS_000452; NCGC00142449-01; 3-(2-Aminoethyl)-1H-indol-5-ol; NCGC00015525-04; 1H-Indol-5-ol,3-(2-aminoethyl)-; 5-hydroxy tryptamine creatinine disulfate; 3-(2-Amino-ethyl)-1H-indol-5-ol; NCGC00015525-03; Enteramin; CCG-204696; bmse000757; QZAYGJVTTNCVMB-UHFFFAOYSA-N; CHEBI:28790; UNII-333DO1RDJY; BSPBio_000341; AN-41571; SCHEMBL1495; BG01504460; PDSP2_001496; Bio1_000939; 5-HT; NCGC00015525-01; FCH832159; BG00601775;Serotonin;AIDS-166243; Indol-5-ol, 3-(2-aminoethyl)-; 5-Hydroxytryptamine; Oprea1_712368; KBio2_007608; Substanz DS; Antemovis; Lopac-H-9523; Thrombocytin; Bio1_000450; Antemoqua; KBio2_000452; Tryptamine, 5-hydroxy-; IDI1_002151; Prestwick0_000481; BPBio1_000377; 5-Hydroxy-3-(beta-aminoethyl)indole; Ds substance; Enteramine; AIDS166243; KBio2_003020; KBioSS_002479; 3-(2-Aminoethyl)indol-5-ol; serotonin; Prestwick2_000481; Bio2_000396; NCGC00142449-01; KBioGR_002472; KBioSS_000452; 3-(2-Aminoethyl)-1H-indol-5-ol; 5-Hta; CAS-153-98-0; KBio2_002472; KBio3_000844; 5-22-12-00016 (Beilstein Handbook Reference); Hippophain; Thrombotonin; NCGC00142449-03; Serotonine; KBio2_005588; Substance DS; Prestwick1_000481; SPBio_002262; NCGC00015525-02; Biomol-NT_000083; KBio3_000843; CHEBI:28790; BSPBio_000341; Bio1_001428; cMAP_000059; BCBcMAP01_000198; EINECS 200-058-9; BB_NC-1185; BRN 0143524; PDSP1_001512; 3-(beta-Aminoethyl)-5-hydroxyindole; PDSP2_001496; 50-67-9; 1H-Indol-5-ol, 3-(2-aminoethyl)-; KBio2_005040; C00780; BPBio1_001079; Bio1_000939; Prestwick3_000481; NCGC00015525-01; KBioGR_000452; Bio2_000876; BSPBio_001112; SMP1_000272; Lopac0_000607; NCGC00142449-04; KBio3_002950 C10H12N2O 176.21 g/mol C1=CC2=C(C=C1O)C(=CN2)CCN
TCMBANKIN060958 oleic acid;cis-oleic acid;oleinic acid C18H34O2 282.46 CCCCCCCCC=CCCCCCCCC(=O)O
TCMBANKIN061006 lauric acid C12H24O2 200.32 CCCCCCCCCCCC(=O)O
TCMBANKIN061045 PENTADECYLIC ACID C15H30O2 242.4 g/mol CCCCCCCCCCCCCCC(=O)O
TCMBANKIN061302 Atropin;atropine C17H23NO3 289.4 g/mol CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3
   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI000166 - - Neoplastic Process disease
TCMBANKDI002512 Digestive System Diseases Abnormality of the digestive system; Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI012979 Immune System Diseases; Chemically-Induced Disorders - Pathologic Function group
TCMBANKDI014645 Pathological Conditions, Signs and Symptoms Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI017700 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI026770 Infections; Respiratory Tract Diseases - Disease or Syndrome disease
TCMBANKDI027289 Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Behavior and Behavior Mechanisms - Mental or Behavioral Dysfunction disease

Home | Browse | Search | Predict | Data | Contact | Help

Copyright © KUST | 滇IICP备16009434号-1 | Dai SX Lab